Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein

US9526777B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Department of Health and Human Services · US
• GLAXOSMITHKLINE BIOLOGICALS SA · BE

Inventors

• Nancy Sullivan · Kensington, US
• Gary J. Nabel · Cambridge, US
• Clement Asiedu · Olney, US
• Cheng Cheng · Bethesda, US
• Alfredo Nicosia · Siena, IT
• Riccardo Cortese · Roma, IT
• Virginia Ammendola · Napoli, IT
• Stefano Colloca · Roma, IT

Key dates

• Filing date: Apr 15, 2011
• Grant date: Dec 27, 2016
• Expiry date: May 12, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/14134
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebola virus (EBOV) or Marburg virus (MARV).